Decoy Therapeutics advances antiviral drug development with new collaborations and milestones

gr.investing.com (Greek)

Decoy Therapeutics announced progress on its antiviral drug development programs, including new collaborations and upcoming milestones. The company is developing Designable Multi-Antivirals (D-MAVs) targeting multiple viruses. Its COVID-19 program is funded without dilution, with a Phase 1 trial expected in 2027. Decoy's platform uses AI for drug design. Despite a stock price drop, the company has strong liquidity and analysts remain optimistic about its future.


With a significance score of 2.8, this news ranks in the top 13% of today's 31157 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Decoy Therapeutics advances antiviral drug development with new collaborations and milestones | News Minimalist